Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - Ascendis Pharma is participating in the 44th Annual JPMorgan Healthcare Conference, highlighting its focus on commercialization and development of its products, particularly SKYTROFA and YORVIPATH [1][3]. Group 1: Company Overview - The CEO of Ascendis Pharma, Jan Mikkelsen, is set to present at the conference, indicating the company's commitment to engaging with investors and stakeholders [1]. - Scott Smith, the CFO, has initiated the conference call, emphasizing the importance of forward-looking statements for the company's strategic direction [2][3]. Group 2: Forward-Looking Statements - The conference will include forward-looking statements related to commercialization, development expectations for SKYTROFA and YORVIPATH, and revenue growth projections [3]. - Statements will also cover pipeline candidates, their associated costs, and expectations regarding clinical trials and regulatory filings [3].